Speaker Name: Prof. Daniel van Raalte, Professor of Medicine, Chair of Diabetology, Amsterdam University Medical Center, Amsterdam, The Netherlands.

Watch this session to:

• Explore a case of advanced CKMS demonstrating dynamic risk modification with SGLT2i and incretin therapy requiring ongoing treatment adjustment.
• Understand multidomain risk in T2DM with HF and CKD, including glycemia, BP, RAAS activation, obesity, and lifestyle factors driving progression.
• Identify high-risk CKMS using eGFR and UACR thresholds, highlighting albuminuria as a key determinant of cardiorenal risk.
• Gain insights into the role of SGLT2i in HF and CKD based on the DELIVER trial and related HF studies supporting reduction in HF events and cardiorenal risk.
• Evaluate complementary therapies and sequencing strategies, including GLP-1 RA and finerenone, supported by FIDELIO-DKD and FIGARO-DKD trials.